HOXD10 and colorectal carcinoma: Furthermore, we treated CRC cells with the DNMT inhibitor 5-Aza-2′-deoxycytidine (5-Aza-CdR) and subsequently measured the expression and methylation levels of HOXD10. As shown in Figure 2C, 5-Aza-CdR treatment strikingly induced the expression of HOXD10, with an approximately fivefold increase in 5-Aza-CdR-treated cells compared to that in control cells (p < 0.01).